[go: up one dir, main page]

WO2019177375A8 - 2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient - Google Patents

2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient Download PDF

Info

Publication number
WO2019177375A8
WO2019177375A8 PCT/KR2019/002915 KR2019002915W WO2019177375A8 WO 2019177375 A8 WO2019177375 A8 WO 2019177375A8 KR 2019002915 W KR2019002915 W KR 2019002915W WO 2019177375 A8 WO2019177375 A8 WO 2019177375A8
Authority
WO
WIPO (PCT)
Prior art keywords
same
preventing
pharmaceutical composition
active ingredient
pyrimidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/002915
Other languages
French (fr)
Korean (ko)
Other versions
WO2019177375A1 (en
Inventor
정명호
김주빈
전현호
이윤호
이화
강세인
조서현
강주희
김환
김현경
서경아
손정범
김남두
석지윤
이선화
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voronoi Inc
Voronoibio Inc
Original Assignee
Voronoi Inc
Voronoibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voronoi Inc, Voronoibio Inc filed Critical Voronoi Inc
Publication of WO2019177375A1 publication Critical patent/WO2019177375A1/en
Publication of WO2019177375A8 publication Critical patent/WO2019177375A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to 2, 4, 5-substituted pyrimidine derivatives, a method for preparing same, and a pharmaceutical composition for preventing or treating cancer comprising same as an active ingredient. Since the compound exhibits a high inhibitory ability against the epidermal growth factor receptor (EGFR) wild type or mutation, the compound can be effectively used for the treatment of cancer expressing the EGFR wild type or EGFR mutation. The compound has an excellent ability to inhibit the proliferation of lung cancer cell lines and can be particularly useful for the treatment of lung cancer.
PCT/KR2019/002915 2018-03-13 2019-03-13 2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient Ceased WO2019177375A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2018-0029389 2018-03-13
KR20180029389 2018-03-13
KR10-2018-0070258 2018-06-19
KR20180070258 2018-06-19

Publications (2)

Publication Number Publication Date
WO2019177375A1 WO2019177375A1 (en) 2019-09-19
WO2019177375A8 true WO2019177375A8 (en) 2020-06-11

Family

ID=67907894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/002915 Ceased WO2019177375A1 (en) 2018-03-13 2019-03-13 2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient

Country Status (2)

Country Link
KR (1) KR102782739B1 (en)
WO (1) WO2019177375A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI798334B (en) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Erbb/btk inhibitors
HUE073283T2 (en) 2019-03-19 2026-01-28 Voronoi Inc Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR102383200B1 (en) * 2019-10-18 2022-04-06 한국화학연구원 pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
KR102467444B1 (en) * 2019-11-11 2022-11-15 서울대학교산학협력단 Iso-exiguamine A derivatives, preparation method thereof and pharmaceutical composition for use in preventing or treating IDO-1 related disease containing the same as an active ingredient
KR102267662B1 (en) * 2019-11-19 2021-06-22 한국화학연구원 Benzamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
CN113179640B (en) * 2019-11-26 2024-06-25 上海翰森生物医药科技有限公司 Nitrogen-containing polycyclic derivative inhibitor, preparation method and application thereof
CN113493420B (en) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 EGFR tyrosine kinase inhibitors and uses thereof
EP4166553A4 (en) * 2020-06-08 2024-07-17 Hongyun Biotech Co., Ltd. Alkenyl pyrimidine compound, preparation method therefor, and application thereof
TW202227425A (en) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 Heteroaryl derivatives, preparation method for the same, and a pharmaceutical composition comprising the same as an active ingredient
KR102868758B1 (en) 2021-04-13 2025-10-14 뉴베일런트, 아이엔씨. Amino-substituted heterocycles for treating cancers harboring EGFR mutations
EP4380924A4 (en) * 2021-08-02 2025-10-01 Dizal Jiangsu Pharmaceutical Co Ltd NEW PHARMACEUTICAL SALTS AND POLYMORPHOUS FORMS OF AN ERBB AND BTK INHIBITOR
CA3228333A1 (en) * 2021-08-05 2023-02-09 Korea Research Institute Of Chemical Technology Pyrimidine derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CA2771190C (en) * 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US20150166591A1 (en) * 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
CN104860941B (en) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative
HUE055233T2 (en) * 2014-10-11 2021-11-29 Shanghai Hansoh Biomedical Co Ltd The EGFR inhibitor and its preparation and application
CN105601573B (en) * 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-Aminopyrimidine compound and its pharmaceutical composition and application

Also Published As

Publication number Publication date
WO2019177375A1 (en) 2019-09-19
KR20190108079A (en) 2019-09-23
KR102782739B1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
WO2019177375A8 (en) 2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient
CR20210415A (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
PH12020551692A1 (en) 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
EP4520328A3 (en) Heterocyclic compounds as immunomodulators
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
EP4523755A3 (en) Quinazoline derivatives as antitumor agents
MX2025011774A (en) Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
NZ795548A (en) Allosteric egfr inhibitors and methods of use thereof
MX2020013817A (en) Substituted naphthyridinone compounds useful as t cell activators.
MX2020007797A (en) Gcn2 inhibitors and uses thereof.
EP4631507A3 (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
WO2019177374A8 (en) 2, 4, 5-substituted pyrimidine derivative, preparation method therefor, and pharmaceutical composition comprising same as effective ingredient for prevention or treatment of cancer or inflammatory disease
WO2019152419A8 (en) Prc2 inhibitors
WO2020247701A3 (en) Inhibitors of sarm1
MX2021008667A (en) Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12021552898A1 (en) N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
MX418886B (en) Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof
JOP20220107A1 (en) Allosteric EGFR inhibitors and methods of their use
EP4480485A3 (en) Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
WO2020159171A3 (en) Composition comprising streptonigrin and anticancer agent for preventing or treating colorectal cancer
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1
MX2025006620A (en) Compounds and compositions as c-kit kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19766992

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19766992

Country of ref document: EP

Kind code of ref document: A1